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I
n this edition of Kidney International, we
publish 2 series of patients who had un-
dergone kidney transplantation during the
coronavirus disease 2019 (COVID-19)
pandemic that have taken different approaches
to transplant immunosuppressive therapy and
antiviral treatment in the early days of the
developing pandemic in the United Kingdom
and Italy. The first series of 7 cases of COVID-
19 infection in patients who had undergone
kidney transplantation comes from St.
George’s, St. Helier’s, and King’s College Hospi-
tals in south London, United Kingdom,1 and
the second series of 20 cases originates from
Spedali Civili University Hospital in Brescia,
Italy.2 The general opinion regarding viral sus-
ceptibility in transplant recipients based on
previous experience is that immune-
compromised individuals are at greater risk of
severe infection because of an impaired im-
mune system, particularly among those with
concurrent comorbidities. There is a lack of in-
formation about the impact of COVID-19 on
patients who had undergone kidney transplan-
tation, despite over 800,000 global cases being
reported worldwide to date. Now Banerjee
et al.1 provide a real-world experience of man-
aging 7 patients who had undergone kidney
transplantation during the developing
COVID-19 pandemic. Overall, 2 of these recip-
ients were managed on an outpatient basis, and
the other 5 required hospital admission: 4 were
in intensive care units and 1 patient died. This
experience has some important clinical mes-
sages for transplant recipients and for trans-
plant programs. First, successful home
management for patients who are positive
for COVID-19 in the community provides
some reassurance that some milder cases of
kidney transplantation may be successfully
managed without hospitalization. Second, 2
of these reported cases were transplanted
within 3 months of the pandemic being
declared and thus provide experience of clin-
ical outcomes during the period of maximal
medical immunosuppression.1 Patient 3 was
transplanted in December 2019, before the
first case of COVID-19 was reported in the
United Kingdom (January 2020), and pre-
sented on March 10, 2020, at a time when
373 COVID-19 cases had been reported.
This patient developed severe respiratory dis-
ease requiring ongoing ventilation and became
anuric. Patient 5 was transplanted on
February 29, 2020, when the United Kingdom
had recorded 20 cases, and then presented on
March 13, 2020, when 797 COVID-19 cases
had been recorded. In this patient, the graft
has been maintained without severe respira-
tory involvement and the need for ventilation.
During the period from December 2019 until
mid-March 2020, the St. George’s unit per-
formed 32 transplants. Importantly in these
patients from the United Kingdom, the
immunosuppressive management was pre-
dominantly reduction and general supportive
therapy without specific antiviral therapeutics.
In the second series of clinical cases from
Brescia, Italy, a contrasting approach was taken
to the management of 20 patients who had
undergone kidney transplantation who were
infected with COVID-19 with severe acute
respiratory syndrome coronavirus 2 pneu-
monia. In this series by Alberici et al.,2 all pa-
tients had baseline immunosuppression
withdrawn. In 19 of 20 cases, methylpredniso-
lone 16 mg daily was added and antiviral
therapy (lopinavir plus ritonavir, darunavir
plus ritonavir, or darunavir plus cobicistat) and
hydroxychloroquine commenced. In a sub-
group of 6 patients, the humanized anti–
interleukin-6 receptor monoclonal antibody
tocilizumab was also added (see their Table 2
and Supplementary Material2). The choice of
lopinavir þ ritonavir was made to target viral
replication in combination with hydroxy-
chloroquine, which was added to help reduce
viral replication. Dexamethasone and tocilizu-
mab, given to counter the cytokine storm, were
felt to be critical in acute respiratory distress
syndrome seen with COVID-19 infection.
Despite these impressive, seemingly logical
therapeutic interventions and use of supportive
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given as has been suggested by others to be
essential in combination with hydroxy-
chloroquine), the clinical outcomes for the
transplant patients were poor with 25% mor-
tality mainly due to complications from
pneumonia. The renal outcomes for the pa-
tients who had undergone kidney trans-
plantation included 6 patients with acute
kidney injury and 1 patient requiring hemo-
dialysis. Furthermore, the use of this complex
combination of agents in critically ill patients is
not also without risks because prolongation of
the cardiac QTc interval by both hydroxy-
chloroquine and lopinavir plus ritonavir have
been reported. More importantly, a recently
published trial of lopinavir plus ritonavir found
no significant benefits in terms of viral clear-
ance and survival between the treatment and
the no-treatment arms. Moreover, both anti-
viral agents interact with calcineurin inhibitors,
causing marked inhibition of metabolism and
potentially high readings. So, what can we take
from these first fascinating reports? First, the
investigators should be congratulated for initi-
ating bold, logical, yet different antiviral stra-
tegies very early on in the pandemic, allowing
the transplant world to see the first results of
antiviral therapy in immunocompromised pa-
tients who had undergone transplantation.
While the current evidence is largely extrapo-
lated from observational data and case series,
the novel clinical experience with anti–inter-
leukin-6, which was applied in worsening res-
piratory cases by Alberici et al.,2 provided some
potential hope that this strategy might be
helpful in the future and could be a potential
component for future trials. However, the
approach of aggressive immunosuppression
withdrawal and anti-inflammatory combina-
tion of drugs did not achieve the survival
benefits we would have hoped for. By contrast,
the smaller series from the United Kingdom
with more gentle immunosuppression reduc-
tion and no anti-inflammatory drugs still had
poor outcomes (14% mortality), but 2 patients
were managed in the community with this
approach. The use of hydroxychloroquine in
the patients in Italy did not seem to provide
any additional benefit compared with those in
the patients in the United Kingdom. Of note,
the first reported kidney transplantation
recipient in the world from Wuhan3 also had
undergone immunosuppression minimization
and kept the transplant.
Unfortunately, many confounding and se-
lection biases, not least of which is the small
sample size in both studies, do not allow us to
draw firm conclusions from these fascinating
first experiences. Other strategies including
switch therapies from tacrolimus to cyclo-
sporine (with its known in vitro antiviral effect)
are potential avenues for future exploration.
However, taken together, these important
early experiences underscore the increased risk
to recipients of kidney transplantation during
the developing pandemic and strongly support
the decision to suspend transplantation pro-
grams (where possible) except for exceptional
cases. Sharing clinical experience with these
cases is crucial and the editors of Kidney In-
ternational would like to inform our readers of
the link to the International Transplantation
Societies roundup of COVID-19 responses
(https://tts.org/txjcovid19).
The clinical management of patients with
COVID-19 infection who had undergone kid-
ney transplantation will clearly vary with clin-
ical presentation and with growing experience
from transplant units worldwide. Randomized
trials will likely be impossible in this situation
and therefore publishing cases and interna-
tional efforts to gather information and
develop a data repository from around the
world will provide the information the field
needs to move forward safely after this
pandemic ends.
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